Mesoblast Limited (NASDAQ:MESO – Get Free Report) saw unusually large options trading on Friday. Traders acquired 5,222 put options on the company. This is an increase of approximately 235% compared to the typical volume of 1,561 put options.
Analysts Set New Price Targets
A number of research firms have recently commented on MESO. Chardan Capital lowered their target price on Mesoblast from $2.00 to $1.50 and set a “sell” rating on the stock in a research note on Friday. StockNews.com assumed coverage on Mesoblast in a research report on Thursday, May 18th. They issued a “sell” rating for the company. Piper Sandler lowered Mesoblast from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $7.00 to $2.00 in a research note on Friday. Finally, William Blair cut Mesoblast from an “outperform” rating to a “market perform” rating in a report on Friday. Two analysts have rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $8.63.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the stock. Vident Investment Advisory LLC increased its stake in Mesoblast by 12.8% in the 4th quarter. Vident Investment Advisory LLC now owns 28,080 shares of the company’s stock worth $82,000 after purchasing an additional 3,191 shares in the last quarter. Signaturefd LLC increased its position in shares of Mesoblast by 199.4% during the second quarter. Signaturefd LLC now owns 10,855 shares of the company’s stock valued at $42,000 after purchasing an additional 7,230 shares during the period. Aries Wealth Management bought a new stake in shares of Mesoblast during the first quarter worth $33,000. EWA LLC acquired a new position in shares of Mesoblast during the first quarter valued at $40,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new position in Mesoblast in the first quarter valued at about $41,000. Institutional investors and hedge funds own 2.60% of the company’s stock.
Mesoblast Stock Down 58.9 %
Mesoblast (NASDAQ:MESO – Get Free Report) last issued its earnings results on Thursday, May 25th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.05. The firm had revenue of $1.94 million for the quarter, compared to analysts’ expectations of $1.80 million. Mesoblast had a negative net margin of 1,043.64% and a negative return on equity of 16.27%. Equities analysts predict that Mesoblast will post -0.58 EPS for the current year.
Mesoblast Company Profile
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases.
Featured Articles
- Five stocks we like better than Mesoblast
- High Dividend REITs: Are They an Ideal Way to Diversify?
- 3 Best Meme ETFs to Buy Now
- Most Active Stocks: Dollar Volume vs Share Volume
- XPO Keeps Reaching New Highs: Markets Love the Stock
- Investing in Agriculture 101: How to Invest in Agriculture
- Starbucks Market at a Turning Point: Is a Breakout Imminent?
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.
